Conference Coverage

SGLT inhibition back on track in phase 3 type T1DM trial

Publish date: October 18, 2017

 

AT EASD 2017

Pages

Recommended Reading

Semaglutide aids T2DM weight loss over 2 years
MDedge Family Medicine
Insulin pumps associated with lower risk of ketoacidosis and severe hypoglycemia in kids
MDedge Family Medicine
Intensified approach reduces long-term heart failure risk in T2DM
MDedge Family Medicine
Triple therapy for type 2 diabetes goes beyond glucose control
MDedge Family Medicine
Intensive exercise didn’t improve glycemic control for obese pregnant women
MDedge Family Medicine
Pediatric psoriasis carries sharply increased risk of selected autoimmune comorbidities
MDedge Family Medicine
Nearly 10% of patients with candidemia had CDI
MDedge Family Medicine
Exercise reduces T1DM mortality risk
MDedge Family Medicine
Oral semaglutide achieves outcomes similar to those of subcutaneous semaglutide
MDedge Family Medicine
Vitality predicts T2DM major cardiovascular event risk
MDedge Family Medicine